Fresh frozen plasma (FFP) is used for patients with one or more coagulation factor deficiencies who are bleeding or at risk of bleeding, and where a specific alternative therapy or factor concentrate is unavailable.
FFP may be indicated to replace labile plasma coagulation factors during
Plasma exchange with FFP is an accepted treatment for patients with thrombotic thrombocytopenic purpura (TTP).
Refer to the National Blood Authority’s Patient Blood Management Guidelines and other evidence-based clinical guidelines for specific guidance to support clinical decisions about appropriate transfusion practices and the use of blood components.
Our Prescribing fresh frozen plasma resource provides guidance for FFP transfusion based on the above guidelines.
Do not use FFP in the following circumstances:
In most cases, the dose will be 15 mL/kg. Consider:
Updated May 2025